Enterprise Therapeutics has announced the publication of results from its phase 1 study of ETD001, a long-acting inhaled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback